MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics (NASDAQ: INKT) has been selected to present interim data from its ongoing Phase 2 study at the AACR IO Annual Meeting in Los Angeles. The presentation will focus on their investigation of AgenT-797 in combination with botensilimab and balstilimab (BOT/BAL) for treating refractory gastric cancer patients.
The study specifically targets patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment. The presentation, scheduled for February 25th, will include biomarker analysis from the trial combining iNKT cell therapy with CTLA-4 and PD-1 inhibitors.
MiNK Therapeutics (NASDAQ: INKT) è stata selezionata per presentare dati intermedi del suo studio di Fase 2 durante l'AACR IO Annual Meeting a Los Angeles. La presentazione si concentrerà sulla loro indagine su AgenT-797 in combinazione con botensilimab e balstilimab (BOT/BAL) per il trattamento dei pazienti con cancro gastrico refrattario.
Lo studio è specificamente rivolto a pazienti con cancro gastroesofageo refrattario al PD-1 (GEC) che hanno ricevuto un trattamento di seconda linea o successivo. La presentazione, programmata per il 25 febbraio, includerà l'analisi dei biomarcatori del trial che combina la terapia con cellule iNKT con inibitori di CTLA-4 e PD-1.
MiNK Therapeutics (NASDAQ: INKT) ha sido seleccionada para presentar datos intermedios de su estudio de Fase 2 en la Reunión Anual AACR IO en Los Ángeles. La presentación se centrará en su investigación sobre AgenT-797 en combinación con botensilimab y balstilimab (BOT/BAL) para el tratamiento de pacientes con cáncer gástrico refractario.
El estudio se dirige específicamente a pacientes con cáncer gastroesofágico refractario al PD-1 (GEC) que han recibido tratamiento de segunda línea o posterior. La presentación, programada para el 25 de febrero, incluirá un análisis de biomarcadores del ensayo que combina la terapia con células iNKT con inhibidores de CTLA-4 y PD-1.
MiNK Therapeutics (NASDAQ: INKT)는 로스앤젤레스에서 열리는 AACR IO 연례 회의에서 진행 중인 2상 연구의 중간 데이터를 발표하도록 선정되었습니다. 발표는 AgenT-797와 botensilimab 및 balstilimab (BOT/BAL)의 조합을 사용하여 난치성 위암 환자를 치료하는 연구에 초점을 맞출 것입니다.
이 연구는 2차 또는 이후 치료를 받은 PD-1 난치성 식도 위암(GEC) 환자를 특별히 대상으로 합니다. 2월 25일로 예정된 발표에서는 CTLA-4 및 PD-1 억제제와 함께 iNKT 세포 치료를 결합한 시험의 바이오마커 분석이 포함될 것입니다.
MiNK Therapeutics (NASDAQ: INKT) a été sélectionnée pour présenter des données intermédiaires de son étude de Phase 2 lors de la Réunion Annuelle AACR IO à Los Angeles. La présentation se concentrera sur leur enquête concernant AgenT-797 en combinaison avec botensilimab et balstilimab (BOT/BAL) pour le traitement des patients atteints de cancer gastrique réfractaire.
L'étude cible spécifiquement les patients atteints de cancer gastro-œsophagien réfractaire au PD-1 (GEC) ayant reçu un traitement de deuxième ligne ou ultérieur. La présentation, prévue pour le 25 février, inclura une analyse des biomarqueurs de l'essai combinant la thérapie cellulaire iNKT avec des inhibiteurs de CTLA-4 et PD-1.
MiNK Therapeutics (NASDAQ: INKT) wurde ausgewählt, um Zwischenberichte aus seiner laufenden Phase-2-Studie auf dem AACR IO Annual Meeting in Los Angeles zu präsentieren. Die Präsentation wird sich auf ihre Untersuchung von AgenT-797 in Kombination mit Botensilimab und Balstilimab (BOT/BAL) zur Behandlung von refraktären Magenkrebspatienten konzentrieren.
Die Studie richtet sich speziell an Patienten mit PD-1-refraktärem gastroösophagealen Krebs (GEC), die eine Zweitlinien- oder spätere Therapie erhalten haben. Die Präsentation, die für den 25. Februar geplant ist, wird eine Biomarker-Analyse aus der Studie umfassen, die die iNKT-Zelltherapie mit CTLA-4- und PD-1-Inhibitoren kombiniert.
- Selected for oral presentation at major oncology conference (AACR IO)
- Advancing Phase 2 clinical trial in gastric cancer
- Development of combination therapy targeting multiple pathways
- None.
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company’s ongoing Phase 2 study testing AgenT-797 in combination with Agenus’ lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).
Presentation Details:
Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
Session: Proffered Papers, Session 2
Date and Time: Tuesday, February 25th, 1:00-1:45 p.m. PST
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy, leveraging a unique innate immune cell type that serves as a master regulator of both innate and adaptive immunity. iNKTs combine the cytotoxic capabilities of natural killer (NK) cells with the adaptive memory of T cells, enabling them to elicit a broad range of immune responses in a pathogen-agnostic manner.
AgenT-797 is a scalable, “off-the-shelf” cell therapy product, manufactured by MiNK Therapeutics in Lexington, MA, to deliver transformative treatment solutions to patients.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
What is the Phase 2 study of INKT's AgenT-797 investigating?
When will MiNK Therapeutics present their Phase 2 gastric cancer data?
What type of cancer patients are included in INKT's Phase 2 trial?
What combination therapy is being tested in INKT's Phase 2 gastric cancer trial?
